Evidity Health Capital

Evidity invests only after a product has achieved regulatory clearance and is commercially available — most healthcare venture firms take earlier-stage, pre-revenue or pre-regulatory risk. This evidence-based mandate means portfolio companies like Augmedics and GT Medical Technologies already had FDA-cleared devices on the market when Evidity committed capital. The firm acts as a growth-equity provider for proven technologies that need scale funding, not seed or Series A discovery capital.

Evidity targets three sectors exclusively: medical devices, in vitro diagnostics, and digital health. It explicitly avoids preclinical biotech, drug discovery, and early-stage therapeutics. The portfolio page confirms every active company operates in one of those three lanes — augmented-reality surgery, implantable radiation therapy, voice-based diagnostics, and precision oncology testing.

Canepa Healthcare is Evidity Health Capital's prior name. The firm's own website states it was formerly known as Canepa Healthcare, and the current Evidity entity appears to represent a rebrand or restructuring of the same team and portfolio. No public documents explain the timing or rationale for the name change.

Evidity's website does not disclose whether it leads rounds or acts as a co-investor. Based on its portfolio composition — concentrated bets in late-stage, commercialized companies — the firm likely negotiates substantial minority stakes, but its specific governance and board-seat practices are not public.

Evidity has not publicly described its sourcing model. The portfolio pattern suggests a combination of direct company relationships and relationships with medical-device and digital-health operator networks. None of the named active or exited companies overlap with a visible, repeatable syndicate of co-investors in public filings.